Nasdaq

Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting

CAMBRIDGE, MA / ACCESSWIRE / May 19, 2023 / Moderna,Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reported on interim data from the Phase 1/2 ...
USA Today

Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)

Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to commercial and sales milestones and tiered royalties on net sales CAMBRIDGE, MA / ...
Nasdaq

Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)

mRNA-3927 uses the same proprietary LNP formulation as mRNA-1944 (antibody against Chikungunya virus) and mRNA-3704 (methylmalonic acidemia) “Fast Track designation underscores the urgent need for a ...
Monthly Prescribing Reference

Carbaglu Approved for Hyperammonemia in Propionic Acidemia, Methylmalonic Acidemia

The Food and Drug Administration (FDA) has approved a new indication for Carbaglu ® (carglumic acid; Recordati Rare Diseases) for use as adjunctive therapy in the treatment of acute hyperammonemia due ...